These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 3517395)

  • 1. Passive transfer of antibodies to human T-cell lymphotropic virus type III in patients receiving high-dose intravenous immunoglobulin.
    White WB; Ryan RW; Staley DD; Ballow M
    JAMA; 1986 May; 255(19):2602-3. PubMed ID: 3517395
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis B immune globulin and human immunodeficiency virus antibody.
    CMAJ; 1988 Sep; 139(6):520. PubMed ID: 3165686
    [No Abstract]   [Full Text] [Related]  

  • 3. [Safety of immunoglobulins in view of the transmission of LAV/HTLV-III].
    Sugg U; Kaufmann R; Gürtler L; Schneider W
    Beitr Infusionther Klin Ernahr; 1987; 18():39-41. PubMed ID: 3326597
    [No Abstract]   [Full Text] [Related]  

  • 4. [Anti-HIV antibodies in patients treated with intravenous gammaglobulins].
    Ohno T; Kanoh T; Fujii H; Okada T; Funakoshi N; Uchino H
    Nihon Ketsueki Gakkai Zasshi; 1987 May; 50(3):649-53. PubMed ID: 2447736
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety of immune globulin preparations.
    CMAJ; 1988 Sep; 139(6):522. PubMed ID: 3165687
    [No Abstract]   [Full Text] [Related]  

  • 6. Human T-lymphotropic virus seroconversion associated with pooled human intravenous immunoglobulin therapy.
    Hunter M; Kiernan MC; Post J
    Intern Med J; 2012 Jun; 42(6):729-30. PubMed ID: 22697159
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence of human T-lymphotropic virus type III antibodies among patients in dialysis programs at a university hospital.
    Morrison AJ; Freer CV; Poole CL; Johnston DO; Westervelt F; Normansell DE; Wenzel RP
    Ann Intern Med; 1986 Jun; 104(6):805-7. PubMed ID: 3518563
    [No Abstract]   [Full Text] [Related]  

  • 8. Screening for antibodies to LAV/HTLV-III in recipients of immunoglobulin preparations.
    Lancet; 1986 May; 1(8489):1090-2. PubMed ID: 2871353
    [No Abstract]   [Full Text] [Related]  

  • 9. Passive immunization of rhesus macaques against SIV infection and disease.
    Gardner M; Rosenthal A; Jennings M; Yee J; Antipa L; Robinson E
    AIDS Res Hum Retroviruses; 1995 Jul; 11(7):843-54. PubMed ID: 7546912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HTLV-III antibodies after immune globulin.
    Piszkiewicz D
    JAMA; 1987 Jan; 257(3):316. PubMed ID: 3467073
    [No Abstract]   [Full Text] [Related]  

  • 11. [Human T-lymphotropic virus (HTLV-III) antibodies in intravenous drug addicts from the Valencia community].
    Rodrigo JM; Serra MA; Aguilar E; Ample I; Gimeno V; del Olmo JA; Escudero A; Aparisi L; Wassel A; Sanmartín B
    Med Clin (Barc); 1986 Jan; 86(3):89-92. PubMed ID: 3007886
    [No Abstract]   [Full Text] [Related]  

  • 12. [Analysis of antibodies to human T-lymphotropic type III virus (anti-HTLV III) in a population at high risk for AIDS in Yugoslavia].
    Burek V; Sakoman S; Hudolin V; Kovać D; Ficović P; Cepelja Z; Petricević I; Schönwald S; Soldo I; Borcić D
    Lijec Vjesn; 1987 Jun; 109(6):216-9. PubMed ID: 3477674
    [No Abstract]   [Full Text] [Related]  

  • 13. Limitations of enzyme immunoassay tests for detection of HTLV-III/LAV antibodies.
    Lyons SF; McGillivray GM; Coppin AP; Schoub BD
    S Afr Med J; 1985 Oct; 68(8):575-6. PubMed ID: 2996159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of an intravenous immunoglobulin preparation: lack of seroconversion for human immunodeficiency virus antibodies.
    Lee ML; Kingdon HS; Hooper J; Courter SG; Holst SL; Piszkiewicz D
    Clin Ther; 1987; 9(3):300-3. PubMed ID: 3111704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin G in viral respiratory infections for newborns and infants.
    Hemming VG; Prince GA
    Pediatr Infect Dis; 1986; 5(3 Suppl):S204-6. PubMed ID: 3714525
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of life-threatening infections in renal transplant recipients with high-dose intravenous human IgG.
    Condie RM; Hall BL; Howard RJ; Fryd D; Simmons RL; Najarian JS
    Transplant Proc; 1979 Mar; 11(1):66-8. PubMed ID: 222019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevalence of antibodies against human T-lymphotropic virus type III (HTLV-III) in parenteral drug addicts in the Barcelona area].
    Muga R; Tor J; Argelagués E; Rey-Joly C; Foz M; Ribas-Mundó M
    Med Clin (Barc); 1986 Jan; 86(3):97-9. PubMed ID: 3457230
    [No Abstract]   [Full Text] [Related]  

  • 18. Human T-lymphotropic virus type III/lymphadenopathy-associated virus antibody prevalence in U.S. military recruit applicants.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1986 Jul; 35(26):421-4. PubMed ID: 3014305
    [No Abstract]   [Full Text] [Related]  

  • 19. Leads from the MMWR. Human T-lymphotropic virus type III/lymphadenopathy-associated virus antibody prevalence in US military recruit applicants.
    JAMA; 1986 Aug 22-29; 256(8):975-7. PubMed ID: 3016355
    [No Abstract]   [Full Text] [Related]  

  • 20. Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III.
    Ward JW; Grindon AJ; Feorino PM; Schable C; Parvin M; Allen JR
    JAMA; 1986 Jul; 256(3):357-61. PubMed ID: 3014173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.